MIRENA (levonorgestrel) by Bayer. Approved for progestin [epc]. First approved in 2000.
Drug data last refreshed 6h ago · AI intelligence enriched 2d ago
MIRENA is a levonorgestrel-releasing intrauterine system (IUS) approved in 2000 that delivers a synthetic progestin directly to the uterus for long-acting contraception and menstrual management. It functions as a hormone-releasing device that prevents pregnancy through local and systemic progestin effects. The product is indicated for contraception and reduction of menstrual bleeding in women of reproductive age.
MIRENA is in peak commercial maturity with modest Part D spending, indicating a stable but mature franchise facing imminent patent expiration in 3.2 years.
Progestin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function Among Young African Women
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on MIRENA at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
MIRENA offers limited immediate career opportunities given zero linked job postings and approaching patent expiration. Roles on this franchise are increasingly focused on managed decline, pricing defense, and transition planning rather than growth-oriented activities. Career mobility on this product may face constraints as Bayer redirects resources toward newer contraceptive platforms and growth-stage franchises.